Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in pediatric chronic graft vs. host disease
NCT03774082Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Novartis. Started May 2020; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03774082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774082.